GlassScriptPhysician profile
Sierra L Davis
NPI 1235510793
$788.68
in general payments reported to CMS, 2019-2025
17 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $268 · 2021: $147 · 2022: $23.61 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $121.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $138.24 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.95 | 2025 | |
| Lilly USA, LLC | $103.16 | 2019-2021 | |
| Abbvie INC. | $95.60 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $45.10 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $43.88 | 2019-2020 | |
| Allergan, INC. | $37.35 | 2020 | |
| Avanir Pharmaceuticals, INC. | $32.88 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.66 | 2019 | |
| Nevro Corp. | $26.99 | 2020 | |
| Amgen INC. | $24.53 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.45 | 2019 | |
| Abbott Laboratories | $16.36 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.85 | 2019 | |
| Novo Nordisk INC | $13.81 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.54 | 2019 | |
| Glaxosmithkline, LLC. | $11.33 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sierra Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.